Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma

Author： Jang Sekwon   Zheng Chaoyi   Tsai Huei-Ting   Fu Alex Z.   Barac Ana   Atkins Michael B.   Freedman Andrew N.   Minasian Lori   Potosky Arnold L.  

Publisher： Blackwell Publishing

E-ISSN： 1097-0142|122|1|124-130

ISSN： 0008-543X

Source： Cancer, Vol.122, Iss.1, 2016-01, pp. : 124-130

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anti-Angiogenic Targets in the Treatment of Advanced Renal Cell Carcinoma

By  

Current Cancer Drug Targets, Vol. 8, Iss. 8, 2008-12 ,pp. : 676-682

Bentham Science Publishers

Access to resources Recommend Favorite

Experimental therapy for advanced renal cell carcinoma

By Hutson Thomas E   Figlin Robert A  

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 11, 2008-11 ,pp. : 1693-1702

Informa Healthcare

Access to resources Recommend Favorite

Targeted-Therapy in Advanced Renal Cell Carcinoma

By  

Current Medicinal Chemistry, Vol. 18, Iss. 11, 2011-04 ,pp. : 1651-1657

Bentham Science Publishers

Access to resources Recommend Favorite

Antiangiogenic treatments and mechanisms of action in renal cell carcinoma

By Négrier Sylvie  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1791-1801

Springer Publishing Company

Access to resources Recommend Favorite

Everolimus: In Advanced Renal Cell Carcinoma

By Garnock-Jones Karly P.   Keating Gillian M.  

Drugs, Vol. 69, Iss. 15, 2009-10 ,pp. : 2115-2124

Adis International

Access to resources Recommend Favorite